Welcome to the Montana Chapter of the American College of Cardiology
Welcome to the Montana Chapter of the American College of Cardiology
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- Veradigm to Conclude Practice-Based Registries After 2025 MIPS SubmissionVeradigm has announced that it will discontinue its Practice Based Registries (the Cardiology Registry and the Metabolic Registry) following completion of the 2025 Merit based Incentive Payment System (MIPS) submission period, expected to conclude on or around March 31, 2026.
- Off-Label Transcatheter Tricuspid Valve Interventions Demonstrate Reduced Residual TR, Improved QOL | NCDR StudyOff-label use of transcatheter tricuspid valve interventions varied greatly across institutions; however, in the majority of tricuspid transcatheter edge-to-edge repair (T-TEER) and transcatheter tricuspid valve replacement (TTVR) cases analyzed, these interventions reduced residual tricuspid regurgitation (TR) to at least moderate severity, and patients saw improved quality of life (QOL), according to a study published in […]
- Emerging Trends in Multimodality Cardiovascular Imaging at AHA25The American Heart Association (AHA) Scientific Sessions 2025 (AHA25) highlighted how quickly cardiovascular (CV) imaging is shifting toward integrated, biology-centered care.
- Change in Renal Function Associated With Difference in 1-Year Survival Post Mitral TEER | NCDR StudyIn patients who underwent mitral transcatheter edge-to-edge repair (TEER), a greater than 10% change in estimated glomerular filtration rate (eGFR) was associated with differences in survival at one year, according to a study using data from the STS/ACC TVT Registry published in Structural Heart.
- HF Hospitalization Risk in T2D Lower With GLP-1RAs Than DPP-4 Inhibitors, Similar With SGLT-2 InhibitorsIn patients with type 2 diabetes (T2D), the risk of hospitalization for heart failure (HHF) was significantly lower with GLP-1RAs than DPP-4 inhibitors while it was similar compared with SGLT-2 inhibitors, according to results from real-world emulation trials published Feb. 24 in Circulation.
